Australian cell therapy company Cartherics will present at the upcoming 2023 BIO International Convention in Boston.
The BIO convention is the world’s largest annual gathering of the life sciences industry. The four-day, in-person event includes networking, programming and partnering opportunities.
Cartherics CEO Professor Alan Trounson will present on 7 June on the company's pipeline, R&D activities, business objectives, and investment goals. Professor Trounson will also meet with senior industry executives, business development leaders and investors.
The company's portfolio includes an autologous CAR-T cell product, scheduled to enter the clinic in 2024, as a potential treatment for ovarian cancer.
It also has an allogeneic immune cell platform consisting of CAR-iNK and CAR-iT cell products targeting solid tumours derived from gene-edited induced pluripotent stem cells). The lead CAR-iNK product is expected to enter clinical trials in 2025.
“BIO is a special place to present for a biotech company because most of the industry is represented there, with great partnering opportunities and potential investment interests. It allows us to present our exciting immune therapies developments to the world,” said Professor Trounson.